Search results
Results From The WOW.Com Content Network
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024. ... Revenue from COVID products fell to $12.5 billion in 2023, down 78% from the $57 billion of peak in 2022. Analysts expect ...
Pfizer now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior forecast of $2.15 to $2.35. ... Pfizer was disappointed with its 2023 launch of RSV shot ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from it prior forecast of $67 billion to $70 billion. It said the reduction was solely due to lowered ...
Pfizer is part of major stock indices like the S&P 100 and S&P 500, having major institutional investors. [4] Pfizer is one of the top pharmaceutical companies in the United States, with a market capitalization of $150.35 billion as of December 31, 2024. It ranks fifth among U.S. pharma companies.
The following is a list of publicly traded companies having the greatest market capitalization, sometimes described as their "market value": [1]. Market capitalization is calculated by multiplying the share price on a selected day and the number of outstanding shares on that day.
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...
Zoetis Inc. (/zō-EH-tis/ [4]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. [5] [4] [6] The company was a subsidiary of Pfizer, [7] the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company.